All posts by: Michael Zand

FDA announces action against two stem cell clinics: Is that a ‘crackdown’?
HealthNewsReview.org
Numerous news outlets covered the FDA’s announcements yesterday (see here and here) of enforcement action against two stem cell clinics that were alleged to offer unapproved and unsafe treatments. Many reports framed the announcement as a …
FDA Targets Unproven, Risky Treatment in Stem Cell Clinics …Newsmax
FDA cracks down on stem cell clinics | WPMT FOX43FOX43.com
FDA warns US Stem Cell Clinic in Sunrise, Florida, of significant deviationsFlorida Trend
Deccan Chronicle –Pain News Network
all 24 news articles »

TCR2 Therapeutics to Present Solid Tumor Data at CAR-TCR Summit and CRI-CIMT-EATI-AACR International Cancer …
Markets Insider
The oral presentations will discuss rationales and mechanisms for its MHC-independent TRuC™-T cells and provide additional preclinical data for TC-210, the company’s lead program targeting mesothelin-positive solid tumors including ovarian, pancreatic …

and more »

SGI-DNA Sees Deal with Belgium’s VIB as Springboard to Building European Synthetic Genomics Business
GenomeWeb
“Europe is a very large market for synthetic biology and we see particular promise in Belgium, Germany, France, Switzerland, and the UK,” Wood said. “From our perspective, research is advancing in these areas as the governments invest in research into …

SGI-DNA Sees Deal With Belgium’s VIB as Springboard to Building European Synthetic Genomics Business
GenomeWeb
“Europe is a very large market for synthetic biology and we see particular promise in Belgium, Germany, France, Switzerland, and the UK,” Wood said. “From our perspective, research is advancing in these areas as the governments invest in research into …

Boosting immune cell memory to improve vaccines and cancer …
Science Daily
Drugs that activate the cells’ proteasome, or recycling center, tip the balance in favor of memory CD8+ T cells, studies on mice show. This approach could be …

and more »

Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T
BioPharma-Reporter.com
Gilead will also add a chimeric antigen receptor (CAR) T-cell manufacturing facility in El Segunda, California which opened in June last year and has the capacity to produce volumes of the autologous therapy for up to 4,000-5,000 patients per year.
Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT
Gilead’s Plan? Cash In on CAR–TMotley Fool
Gilead just handed a revolutionary kind of cancer treatment a $12 billion endorsementBusiness Insider
Barron’s –Xconomy –Zacks Investment Research
all 333 news articles »

Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T
BioPharma-Reporter.com
Gilead will also add a chimeric antigen receptor (CAR) T-cell manufacturing facility in El Segunda, California which opened in June last year and has the capacity to produce volumes of the autologous therapy for up to 4,000-5,000 patients per year.
Gilead agrees to buy Kite Pharma, leaping into CAR–T cancer therapySTAT
Gilead’s Plan? Cash In on CAR–TMotley Fool
Gilead just handed a revolutionary kind of cancer treatment a $12 billion endorsementBusiness Insider
Barron’s –Xconomy –Zacks Investment Research
all 333 news articles »